06:11 EDT Kenvue (KVUE) rallies 6% to $18 after Trump event on Tylenol risk
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Barclays ‘rough math’ suggests Kenvue selloff overdone
- Citi sees Kenvue rallying on Trump’s lack of scientific evidence
- Hold Rating for Kenvue, Inc. Amidst Market Reaction to Government Advisories on Acetaminophen
- Kenvue Stock (KVUE) Pops, Defying Trump’s Claim Linking Tylenol to Autism
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!